Infliximab-associated focal segmental glomerulosclerosis in a patient with ankylosing spondylitis
- 45 Downloads
The introduction of tumor necrosis factor-alpha (TNF-α)-targeting drugs has given new opportunities in the treatment of various inflammatory rheumatic diseases and has been the most important development in the treatment of spondyloarthritis (SpA). However, the increasing use and longer follow-up periods of treatment also pose risks of developing various adverse effects ranging from common ones including infections to uncommon renal complications. This report describes a case of infliximab-induced focal segmental glomerulosclerosis (FSGS) in a 40-year-old female patient with ankylosing spondylitis (AS) who presented with asymptomatic proteinuria and microscopic hematuria. To the best of our knowledge, this is the second reported case of FSGS attributed to infliximab (IFX). A review of the English literature was conducted for cases of possible IFX-associated renal disorders in patients with SpA and SpA spectrum diseases. In this respect, the reported renal pathologies were IgA nephropathy, crescentic glomerulonephritis, acute renal artery occlusion, acute tubulointerstitial nephritis (ATIN), FSGS, and membranous glomerulopathy. Furthermore, partial or complete resolution was reported after cessation of therapy. In conclusion, although renal complications of TNF inhibitors (TNFi) are uncommon, spot urine evaluation may be recommended in the follow-up of patients treated with TNFi.
KeywordsInfliximab Focal segmental glomerulosclerosis Ankylosing spondylitis
All the authorship contributions were declared in line with the ICMJE 4 criteria: Dr. Yarkan Tuğsal and Dr. Birlik wrote the paper. Dr. Zengin and Dr. Kenar searched the databases for review of the literature. Dr. Can and Dr. Önen read the selected articles and evaluated for eligibility. Dr. Ünlü evaluated pathology of the kidney. Dr. Yarkan Tuğsal, Dr. Kenar and Dr. Birlik revised the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
There is no source(s) of support in the form of grants or industrial support.
Compliance with ethical standards
Conflict of interest
All the authors declare that they have no conflicts of interest.
The patient gave a written informed consent before written.
- 1.Samson M, Espigol-Frigole G, Terrades-Garcia N, Prieto-Gonzalez S, Corbera-Bellalta M, Alba-Rovira R, Hernandez-Rodriguez J, Audia S, Bonnotte B, Cid MC (2018) Biological treatments in giant cell arteritis & Takayasu arteritis. Eur J Intern Med 50:12–19. https://doi.org/10.1016/j.ejim.2017.11.003 CrossRefGoogle Scholar
- 15.Sato T, Kawasaki Y, Ito A, Izumi H, Kawamorita N, Yamashita S, Mitsuzuka K, Matsuura T, Watanabe M, Arai Y (2018) Infliximab-Induced Tubulointerstitial Nephritis with Image Findings of Striated Nephrogram in Crohn’s Disease. Tohoku J Exp Med 245(3):149–152. https://doi.org/10.1620/tjem.245.149 CrossRefGoogle Scholar
- 16.Piga M, Chessa E, Ibba V, Mura V, Floris A, Cauli A, Mathieu A (2014) Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort. Autoimmun Rev 13(8):873–879. https://doi.org/10.1016/j.autrev.2014.05.005 CrossRefGoogle Scholar
- 22.Vogt L, Laverman GD, Navis G (2010) Time for a comeback of NSAIDs in proteinuric chronic kidney disease? Neth J Med 68(12):400–407Google Scholar
- 23.de Borst MH, Nauta FL, Vogt L, Laverman GD, Gansevoort RT, Navis G (2012) Indomethacin reduces glomerular and tubular damage markers but not renal inflammation in chronic kidney disease patients: a post-hoc analysis. PLoS One 7(5):e37957. https://doi.org/10.1371/journal.pone.0037957 CrossRefGoogle Scholar